Achillion raising $56.6 million to advance hepatitis C candidates
This article was originally published in Scrip
Executive Summary
Achillion Pharmaceuticals on 22 June priced a public offering of 9.6 million shares of its common stock at $5.90 per share, a modest discount to the closing price of $6.01 on 21 June, raising $56.6 million. The firm expects net proceeds of about $52.9 million.